A Phase 1, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10342 in Patients With Advanced Solid Tumor
Latest Information Update: 13 Mar 2023
At a glance
- Drugs HS 10342 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Jiangsu Hansoh Pharmaceutical
- 07 Mar 2023 Status changed from recruiting to completed.
- 25 Aug 2019 New trial record